A national, prospective single arm phase II study investigating the pharmacokinetics and safety of the 2% TD1414 cream when applied 3 times daily for 7 days to adult patients with impetigo or Secondarily Infected Traumatic Lesions (SITL). A total of 20 patients will be enrolled.

开始日期2008-12-01

申办/合作机构

Leo Pharma, Inc.

NCT00626795

/ Completed临床2期

Efficacy, Safety and Tolerability of TD1414 2% Cream in Impetigo and Secondarily Infected Traumatic Lesions (SITL)

An international, multi-centre, prospective three arm parallel-group, phase II proof of concept study comparing the efficacy and safety of two dosage regimens (BID 7 days and TID 7 days) of TD1414 2% cream and one dosage regimen (BID 7 days) of Bactroban® (mupirocin) 2% cream in adults and children down to 2 years of age with impetigo or SITL. Furthermore an evaluation of the pharmacokinetics of TD1414 2% cream TID for 7 days will be performed. A total of 664 patients will be enrolled in a stepwise manner according to age groups starting with the oldest age group.

开始日期2008-02-01

申办/合作机构

Leo Pharma, Inc.

100 项与 TD-1414 相关的临床结果

登录后查看更多信息

100 项与 TD-1414 相关的转化医学

登录后查看更多信息

100 项与 TD-1414 相关的专利（医药）

登录后查看更多信息

项与 TD-1414 相关的文献（医药）

Nature Communications1区 · 综合性期刊

Transport of lipophilic carboxylates is mediated by transmembrane helix 2 in multidrug transporter AcrB

1区 · 综合性期刊

ArticleOA

作者: Tam, Heng-Keat ; Oswald, Christine ; Pos, Klaas M

AbstractThe deployment of multidrug efflux pumps is a powerful defence mechanism for Gram-negative bacterial cells when exposed to antimicrobial agents. The major multidrug efflux transport system in Escherichia coli, AcrAB–TolC, is a tripartite system using the proton-motive force as an energy source. The polyspecific substrate-binding module AcrB uses various pathways to sequester drugs from the periplasm and outer leaflet of the inner membrane. Here we report the asymmetric AcrB structure in complex with fusidic acid at a resolution of 2.5 Å and mutational analysis of the putative fusidic acid binding site at the transmembrane domain. A groove shaped by the interface between transmembrane helix 1 (TM1) and TM2 specifically binds fusidic acid and other lipophilic carboxylated drugs. We propose that these bound drugs are actively displaced by an upward movement of TM2 towards the AcrB periplasmic porter domain in response to protonation events in the transmembrane domain.

100 项与 TD-1414 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
人咬伤	临床2期	美国	Leo Pharma, Inc.	2008-12-01
烧伤	临床2期	美国	Leo Pharma, Inc.	2008-12-01
脓疱疮	临床2期	美国	Leo Pharma, Inc.	2008-02-01
脓疱疮	临床2期	南非	Leo Pharma, Inc.	2008-02-01
创伤和损伤	临床2期	南非	Leo Pharma, Inc.	2008-02-01
复杂的皮肤和软组织感染	临床2期	美国	LEO Pharma A/S	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT00758862 (CTgov)	临床2期	烧伤 \| 脓疱疮 \| 创伤和损伤 \| 人咬伤	20	TD1414	廠艱憲築糧製窪窪襯鹽(範憲遞壓選積襯繭齋觸) = 糧廠選艱糧廠淵鹹壓醖鏇願築選顧衊鬱衊糧餘 (鹽衊糧夢壓簾醖築選鬱, 餘艱選顧鬱繭廠餘獵獵 ~ 範鬱艱衊觸憲衊範構鬱) 更多	-	2018-07-23
NCT00626795 (CTgov)	临床2期	脓疱疮 \| 创伤和损伤	773	TD1414 (TD1414 BID)	(繭簾壓夢積簾製築憲襯) = 夢廠範糧觸夢壓壓艱鑰膚夢簾遞襯醖衊憲襯繭 (齋廠壓艱糧鹽鏇網鹽獵, 蓋夢獵選鏇齋壓獵窪鑰 ~ 鏇鹽製齋襯鹹築簾醖簾) 更多	-	2018-07-23
NCT00626795 (CTgov)	临床2期	脓疱疮 \| 创伤和损伤	773	TD1414 (TD1414 TID)	(繭簾壓夢積簾製築憲襯) = 觸築膚壓蓋遞範壓築鏇膚夢簾遞襯醖衊憲襯繭 (齋廠壓艱糧鹽鏇網鹽獵, 餘築網觸積襯繭憲膚壓 ~ 壓範繭壓餘獵積壓衊淵) 更多	-	2018-07-23